Trials / Conditions / Peyronie's Disease

Peyronie's Disease

18 registered clinical trials studyying Peyronie's Disease — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease NCT05873595	Endo Pharmaceuticals	—
Unknown	Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease NCT05855070	Benha University	N/A
Active Not Recruiting	Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders NCT05108558	Charitable Union for the Research and Education of Peyronie's Disease	Phase 4
Recruiting	Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cys NCT05147779	The Foundation for Orthopaedics and Regenerative Medicine	Phase 1
Active Not Recruiting	Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's NCT04786106	Charitable Union for the Research and Education of Peyronie's Disease	Phase 4
Unknown	Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Respons NCT03767452	Manhattan Medical Research Practice, PLLC	Phase 4
Completed	Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Tr NCT02298829	Endo Pharmaceuticals	—
Completed	An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® NCT02267460	Endo Pharmaceuticals	Phase 3
Completed	Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD NCT02395029	Melissa Marchand	Phase 1
Completed	Peyronie's Disease Treatment Protocol NCT02072018	Hybrid Medical	Phase 1
Completed	Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease NCT01578473	Men's Health Boston	Phase 1
Completed	A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle f NCT01685437	Endo Pharmaceuticals	Phase 3
Completed	Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease NCT01430169	Endo Pharmaceuticals	Phase 2
Completed	A Study of AA4500 in Men With Peyronie's Disease NCT01243411	Endo Pharmaceuticals	Phase 3
Completed	Study of AA4500 in the Treatment of Peyronie's Disease NCT01221623	Endo Pharmaceuticals	Phase 3
Completed	Study of AA4500 in the Treatment of Peyronie's Disease NCT01221597	Endo Pharmaceuticals	Phase 3
Completed	H-22411: BOTOX® for Peyronie's Disease NCT00812838	Mohit Khera	Phase 2
Completed	The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease NCT00755222	Endo Pharmaceuticals	Phase 2